ArticleDrug target insights2012
Resveratrol Targeting of Carcinogen-Induced Brain Endothelial Cell Inflammation Biomarkers MMP-9 and COX-2 is Sirt1-Independent.
Article in Drug target insights, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Aterofisiol(®) in carotid plaque evolution.Drug design, development and therapy · 2015Trial
- Potential role of resveratrol in abdominal cocoon syndrome: targeting inflammation, oxidative stress, and fibrosis via food-derived bioactive compounds resveratrol for treatment of abdominal cocoon syndrome.Frontiers in pharmacology · 2026Review
- From Microcirculation to Aging-Related Diseases: A Focus on Endothelial SIRT1.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions.Antioxidants (Basel, Switzerland) · 2023Review
- Quercetin and resveratrol ameliorate nickel-mediated hypercontraction in isolated Wistar rat aorta.Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi · 2022Article
- Resveratrol-Induced Signal Transduction in Wound Healing.International journal of molecular sciences · 2021Review
- Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.Neurochemical research · 2021Review
- Inhibition of NF-κB Signaling Pathway by Resveratrol Improves Spinal Cord Injury.Frontiers in neuroscience · 2018Review
- Asiaticoside Attenuates Cell Growth Inhibition and Apoptosis Induced by AβFrontiers in pharmacology · 2018Article
- Thrombopoietin could protect cerebral tissue against ischemia-reperfusion injury by suppressing NF-κB and MMP-9 expression in rats.International journal of medical sciences · 2018Article
- Neuroprotective Mechanisms of Resveratrol in Alzheimer's Disease: Role of SIRT1.Oxidative medicine and cellular longevity · 2018Review
- Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.Cellular and molecular neurobiology · 2018Review
- A study of Sirt1 regulation and the effect of resveratrol on synoviocyte invasion and associated joint destruction in rheumatoid arthritis.Molecular medicine reports · 2017Article
- Targeting extracellular matrix remodeling in disease: Could resveratrol be a potential candidate?Experimental biology and medicine (Maywood, N.J.) · 2017Review
- Article
- Resveratrol and Ophthalmic Diseases.Nutrients · 2016Review
- Resveratrol alleviates vascular inflammatory injury by inhibiting inflammasome activation in rats with hypercholesterolemia and vitamin D2 treatment.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Article
- A Role for the Cavin-3/Matrix Metalloproteinase-9 Signaling Axis in the Regulation of PMA-Activated Human HT1080 Fibrosarcoma Cell Neoplastic Phenotype.Cancer growth and metastasis · 2014Article
- Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.Current pharmaceutical design · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of a functional relationship between the release of metalloproteinases (MMPs) and the expression of cyclooxygenase (COX)-2, two inducible pro-inflammatory biomarkers with important pro-angiogenic effects, has recently been inferred. While brain endothelial cells play an essential role as structural and functional components of the blood-brain barrier (BBB), increased BBB breakdown is thought to be linked to neuroinflammation. Chemopreventive mechanisms targeting both MMPs and COX-2 however remain poorly investigated. In this study, we evaluated the pharmacological targeting of Sirt1 by the diet-derived and antiinflammatory polyphenol resveratrol. Total RNA, cell lysates, and conditioned culture media from human brain microvascular endothelial cells (HBMEC) were analyzed using qRT-PCR, immunoblotting, and zymography respectively. Tissue scan microarray analysis of grade I-IV brain tumours cDNA revealed increased gene expression of Sirt-1 from grade I-III but surprisingly not in grade IV brain tumours. HBMEC were treated with a combination of resveratrol and phorbol 12-myristate 13-acetate (PMA), a carcinogen known to increase MMP-9 and COX-2 through NF-κB. We found that resveratrol efficiently reversed the PMA-induced MMP-9 secretion and COX-2 expression. Gene silencing of Sirt1, a critical modulator of angiogenesis and putative target of resveratrol, did not lead to significant reversal of MMP-9 and COX-2 inhibition. Decreased resveratrol inhibitory potential of carcinogen-induced IκB phosphorylation in siSirt1-transfected HBMEC was however observed. Our results suggest that resveratrol may prevent BBB disruption during neuroinflammation by inhibiting MMP-9 and COX-2 and act as a pharmacological NF-κB signal transduction inhibitor independent of Sirt1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.